Nextgen Biomed Ltd develops drugs for topical treatments for skin diseases. It develops DPS-101, a product that is in the Phase II/b used for the topical treatment of psoriasis without steroids. Nextgen Biomed Ltd has a collaboration agreement with the Boston VA Research Institute Inc. for the realization of Phase II and III of clinical experiments in human beings of DPS. The Company was incorporated in 1990 and is based in Tel Aviv, Israel.
nextgen biomed ltd (NXGN:Tel Aviv)
132 Menahen Begin
Tel Aviv, 67021
Phone: 972 3 607 0320
Fax: 972 3 607 0323--
|No competitor information is available for NXGN.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact NEXTGEN BIOMED LTD, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.